MARKET

FBIO

FBIO

Fortress Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.540
+0.100
+2.91%
After Hours: 3.530 -0.01 -0.28% 16:41 09/24 EDT
OPEN
3.500
PREV CLOSE
3.440
HIGH
3.570
LOW
3.450
VOLUME
536.23K
TURNOVER
--
52 WEEK HIGH
6.10
52 WEEK LOW
2.120
MARKET CAP
357.76M
P/E (TTM)
-8.3609
1D
5D
1M
3M
1Y
5Y
Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment and Drugs Market Global Industry Analysis, Size, Share, Growth and Forecast 2028
Research Nester published a report titled which delivers detailed overview of the head and neck squamous cell carcinoma (HNSCC) treatment and drugs in terms of market segmentation by drug class, distribution channel and by region.
AmericaNewsHour · 3d ago
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will p...
GlobeNewswire · 4d ago
What Kind Of Investors Own Most Of Fortress Biotech, Inc. (NASDAQ:FBIO)?
Every investor in Fortress Biotech, Inc. ( NASDAQ:FBIO ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 09/13 11:33
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. De...
GlobeNewswire · 09/09 12:30
Mustang Bio to Participate in Three September 2021 Investor Conferences
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, t...
GlobeNewswire · 09/09 12:30
BRIEF-Fortress Biotech - On August 26, Avenue Therapeutics Received Appeal Denied Letter From Office Of Neuroscience Of FDA In Response To Its Fdrr
reuters.com · 08/27 21:28
BRIEF-Mustang Bio Q2 Loss Per Share $0.16
reuters.com · 08/16 20:47
Fortress Biotech Q2 EPS $(0.17) Down From $(0.05) YoY, Sales $17.84M Up From $9.46M YoY
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.17) per share. This is a 240 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $17.84 million in sales
Benzinga · 08/16 20:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FBIO. Analyze the recent business situations of Fortress Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FBIO stock price target is 10.17 with a high estimate of 24.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 31.18M
% Owned: 30.85%
Shares Outstanding: 101.06M
TypeInstitutionsShares
Increased
27
1.22M
New
13
164.13K
Decreased
29
2.24M
Sold Out
12
372.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Executive Director
Michael Weiss
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
No Data
About FBIO
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.

Webull offers kinds of Fortress Biotech Inc stock information, including NASDAQ:FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.